Which drug helps men with advanced prostate cancer live longer?
NCT ID NCT05968599
Summary
This study looked at real-world medical records to compare two common drugs for advanced prostate cancer that has spread and stopped responding to standard hormone therapy. Researchers analyzed data from over 2,700 men who started treatment with either enzalutamide or abiraterone. The goal was to see which treatment was associated with longer survival and how long patients stayed on the medication before needing a new therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Inc
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.